Blog

  • Google Hires Filmmaker in Residence to Help Push Flow AI Video Tool

    Google Hires Filmmaker in Residence to Help Push Flow AI Video Tool

    Google wants to see its generative AI video tool Flow gain a foothold among creatives, and is bringing a filmmaker in-house to help it do so.

    The tech giant says that it has brought on filmmaker and creative director Henry Daubrez to work as a filmmaker in residence at Google Labs, where he will create new content using the company’s tools, help shape Flow as a product, and mentor other filmmakers through what the company is calling Flow Sessions.

    Flow Sessions will give participants complimentary access to Flow, as well as guidance and mentorship. Google officially rolled out Flow earlier this year alongside a partnership with Darren Aronofsky and his new venture Primordial Soup.

    “We often only offered text to video [in prior models], but the quality of the model had reached a point where we started seeing highly creative folks starting to create three, four minute kind of shorts. And that told us, okay, there’s something there,” Thomas Iljic, product lead at Google Labs, told The Hollywood Reporter in an interview at the time.

    Daubrez was one of those filmmakers, creating the film Electric Pink using the tool (you can watch that film below). He is also developing The Enchanted Door, a project that will let Flow users jump into the story to decide what happens next.

    Generative AI video tools are proliferating, with some AI-focused filmmakers already using the tools on a daily basis. Meanwhile, every Hollywood studio is AI-curious, hoping that the tools can help drive down costs and increase productivity, even as they remain wary of copyright concerns.

    As one of the world’s largest tech giants, Google’s position in the space is a commanding one, though competition from the likes of Meta, OpenAI and others is fierce. The company is betting that a deeper relationship with creatives can help it stand out in a marketplace where video tools are beginning to expand in quality, availability, and accessibility.

    Continue Reading

  • Trump says China should have mentioned US during 'beautiful ceremony' – Reuters

    1. Trump says China should have mentioned US during ‘beautiful ceremony’  Reuters
    2. Xi Jinping says world faces ‘peace or war’, as Putin and Kim join him for military parade  The Guardian
    3. Trump accuses Xi of conspiring against US with Putin and Kim  BBC
    4. Trump ‘not concerned’ about China and Russia forming axis against US  Al Jazeera
    5. China’s Xi says the world faces ‘peace or war’ as Trump claims Beijing conspiring against U.S.  CNBC

    Continue Reading

  • A Promising Strategy for ER+ Breast Cancer

    A Promising Strategy for ER+ Breast Cancer

    Resistance to endocrine therapy remains a formidable barrier in the management of estrogen receptor–positive (ER+) breast cancer. Although selective ER modulators (SERMs), aromatase inhibitors (AIs), and selective ER degraders (SERDs) can initially control tumor growth, resistance inevitably develops—often while ER signaling persists.1 This underscores the urgent need for novel therapeutic strategies that disrupt ER‑driven transcriptional programs by targeting chromatin regulators.

    Image Credit: Bangkok Click Studio | stock.adobe.com

    The MYST family histone acetyltransferases KAT6A and its paralog KAT6B play a critical role in mediating ER‑driven gene expression. KAT6A is amplified or overexpressed in roughly 10% to 15% of ER+ breast cancers, where its activity correlates with aggressive tumor behavior and poor prognosis.2 A breakthrough inhibitor, PF‑9363 (also CTx-648; Pfizer), has been developed as a potent, selective, and orally bioavailable compound targeting KAT6A/B. In preclinical models, PF‑9363 was shown to suppress H3K23 acetylation and reduce RNA polymerase II binding at estrogen-signaling genes, leading to significant tumor inhibition—even in endocrine-resistant settings.

    Using an epigenetic-focused CRISPR‑Cas9 screen, Menin (encoded by MEN1) was identified as a key codependency in ER+ breast cancer cells treated with PF‑9363. Knockout of MEN1 significantly enhanced sensitivity to KAT6A/B inhibition. Menin, a chromatin adaptor protein often associated with KMT2A/MLL1 complexes, is highly expressed in more than half of breast cancers and strongly associated with ER+ subtypes.

    Synergistic Effects Through Dual Inhibition

    Co‑treatment with KAT6A/B and menin inhibitors—namely PF‑9363 and SNDX‑5613 (revumenib, Revuforj; Syndax Pharmaceuticals)—produces marked synergistic anti‑proliferative effects in ER+ cell lines, but not in ER– models.2 Mechanistically, the combination disrupts ER‑driven transcription through two pivotal actions. First, it reduces ESR1 (ERα) gene and protein expression. Second, it displaces both KAT6A and Menin–KMT2A from the promoters of ER target genes, leading to loss of RNA polymerase II binding and chromatin accessibility in those regions.2,3 These effects are more robust than those produced by either inhibitor alone.

    Efficacy in 3D Organoids and Patient-Derived Xenografts

    The synergy extends beyond cell lines. In 3D patient‑derived organoid (PDxO) models of ER+ breast cancer, including both ductal and lobular carcinoma variants, the combined inhibition displayed enhanced suppression of ER-driven gene expression and organoid growth. Moreover, in patient‑derived xenograft (PDX) models, including those with endocrine-resistant and ESR1-mutated tumors, the dual therapy maintained its efficacy in vivo, highlighting its potential relevance to advanced, treatment‑refractory disease.2

    Both PF‑9363 and SNDX‑5613 are advancing in clinical development. PF‑9363 and other KAT6A/B inhibitors like PF‑07248144 (Pfizer) are undergoing early‑phase trials, with PF‑07248144 already demonstrating a 37% objective response rate and manageable toxicity in heavily pretreated metastatic ER+ breast cancer patients. SNDX‑5613, a menin inhibitor, has received FDA approval for KMT2A‑rearranged leukemia, suggesting a favorable safety profile.2 These developments provide strong ground for considering clinical evaluation of the KAT6A/B plus Menin inhibitor combination in ER+ breast cancer.3

    Conclusion

    The dual inhibition of KAT6A/B and Menin represents a novel epigenetic intervention capable of overriding both endocrine sensitivity and resistance in ER+ breast cancer. By targeting two critical chromatin complexes that jointly sustain ER‑driven transcription, this combination achieves superior suppression of tumor growth and gene expression. With both inhibitor classes already in clinical trials and demonstrating tolerability, this strategy offers a compelling new avenue for personalized therapy, particularly in patients with refractory disease. Future research should assess combination regimens across diverse genomic backgrounds and explore optimal dosing and safety in clinical settings.1

    REFERENCES
    1. KAT6A/B and Menin Inhibition Synergize to Suppress ER+ Breast Cancer | Docwire News. Docwire News. Published 2025. Accessed September 3, 2025. https://www.docwirenews.com/post/kat6a-b-and-menin-inhibition-synergize-to-suppress-er-breast-cancer
    2. Olsen SN, Anderson B, Hatton C, et al. Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. Cell Rep Med. 2025;6(7):102192. doi:10.1016/j.xcrm.2025.102192
    3. Sharma S, Chung CY, Uryu S, et al. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chem Biol. 2023;30(10):1191-1210.e20. doi:10.1016/j.chembiol.2023.07.005

    Continue Reading

  • GP Bullhound is delighted to be advising Matawan on their exclusive negotiations with Antin for a majority investment.

    GP Bullhound is delighted to be advising Matawan on their exclusive negotiations with Antin for a majority investment.

    Antin Infrastructure Partners and Matawan have entered into exclusive negotiations for a majority investment in Matawan, a leading smart mobility platform offering mission critical services to public transport networks and aiming to make everyday travel easier for commuters, transport authorities and operators.

    Based in Paris, Lyon, Mâcon and Sophia-Antipolis and founded in 2012, Matawan offers an end-to-end mobility platform that breaks the silos in public transit. Its Cloud-based solutions serve as the infrastructure backbone of modern transportation systems enabling all essential functions. Matawan simplifies the usage of public transport networks across modes (bus, tram, rail, bikes, ferry…) via account-based ticketing, optimises supply and demand via AI and provides travellers and operators with reliable information and quality of service.

    Matawan today serves more than 300 transport networks across six countries in Europe and North America and is part of French Tech 120, a French government-led programme designed to support the 120 most promising French scale-ups that have the potential to become global leaders. It plans to continue growing its business both organically and through acquisitions, while entering new geographies.

    Antin would be investing in Matawan alongside founder Jean-Paul Medioni, who would sit on the company’s Supervisory Board,  CEO Jérome Tredan and its management team. 

    Upon closing, this investment would be the seventh by Antin’s €1.2 billion NextGen Infrastructure Fund I. NextGen invests in companies that have proven business models and technologies that require substantial capital to scale to become the next generation of infrastructure, often with a strong focus on sustainability.

    Nathalie Kosciusko-Morizet and Nicolas Mallet, NextGen Senior Partner and NextGen Partner, respectively, at Antin Infrastructure Partners, declared: “Matawan is a great fit for our NextGen strategy. The company is perfectly positioned to become a leader in public transport by facilitating the transition to smart, intermodal and interoperable networks, benefiting from a fundamental shift in commuting patterns and the need to decarbonise mobility. We are greatly looking forward to working with Matawan’s teams to help take the company to the next level.”

    Jérôme Tredan, CEO of Matawan, added: “We are thrilled to have the backing of Antin as the company enters a new growth chapter. Antin is the right partner to help us consolidate our French and European leadership, allow us to accelerate our expansion in Europe and North America and execute our vision of making everyday commute easier for all, for a more sustainable future.”

    Jean-Paul Medioni, Matawan’s founder, concluded: “I am particularly proud of the work accomplished with the teams over these exciting years to promote public transport across territories through digital technology and innovation. I am delighted to see the Matawan project take on a new dimension with the support of Antin and a strong management team. I am very motivated by this new chapter in our history and confident in Matawan’s ability to reach new heights.”

    The transaction remains subject to customary works council information procedures and regulatory approval and is expected to close by the end of 2025.

    About Antin Infrastructure Partners
    Antin Infrastructure Partners is a leading private equity firm focused on infrastructure. With over €33 billion in assets under management across its Flagship, Mid Cap and NextGen investment strategies, Antin targets investments in the energy and environment, digital, transport and social infrastructure sectors. With offices in Paris, London, New York, Singapore and Luxembourg, Antin employs over 240 professionals dedicated to growing, improving and transforming infrastructure businesses while delivering long-term value to portfolio companies and investors. Majority owned by its partners, Antin is listed on Euronext Paris (Ticker: ANTIN – ISIN: FR0014005AL0).

    About Matawan
    Matawan simplifies everyday travel by connecting mass transit to all modes of mobility. Thanks to a combination of ticketing, electronic payment, quality of service and data management solutions, its SaaS (Software as a Service) platform helps improve user service, travel with a single ticket and reduce the environmental footprint of journeys. As a partner to local authorities and operators, Matawan works daily at the heart of cities and regions to liberate mobility services for greater inclusivity, sustainability and convenience. Multi-awarded since its creation in 2012 in Burgundy (France), Matawan is today positioned as a driving force in French Tech, of which it has joined FT120. More information on www.matawan-mobility.com

    About GP Bullhound
    GP Bullhound is a leading technology advisory and investment firm, providing transaction advice and capital to the world’s best entrepreneurs. Founded in 1999, the firm has 11 offices across Europe, the US, and Asia. Learn more at www.gpbullhound.com.

    Enquiries
    For enquiries, please contact:
    Joffrey Ezerzer, Joffrey.Ezerzer@gpbullhound.com

    Continue Reading

  • How physical activity may fight Parkinson’s disease symptoms

    How physical activity may fight Parkinson’s disease symptoms

    We know exercise is good for the body and mind. This may be especially true for people with early-stage Parkinson’s disease (PD). According to recent research by UCLA scientists, exercise may help fend off PD symptoms like worsening tremors, stiffness and balance issues.

    Chronic inflammation happens when the immune system becomes overactive in the brain and nervous system. This can bring on PD symptoms.

    “Prior research has found that a decrease in inflammation can play a crucial role in preventing or delaying the progression of PD,” says Yang Chen Hu, PhD, lead study author.

    There is still much to learn about long-term inflammation, says Dr. Hu. However, the study findings suggest that exercise can help people with PD feel better for longer.

    Dr. Hu is an epidemiology student in the laboratory of Beate Ritz, MD, PhD, a professor of epidemiology at the UCLA Fielding School of Public Health with a co-appointment in the department of neurology at the David Geffen School of Medicine at UCLA.

    Dr. Ritz was one of the study’s senior authors, as was Cynthia Kusters, MD, PhD, an assistant professor in the Department of Epidemiology at the UCLA Fielding School of Public Health.

    “Our work takes a novel approach to studying inflammation, helping us understand how behavior and environmental exposures influence biological processes,” says Dr. Kusters.

    “This offers promising opportunities for studying how lifestyle factors and exposures relate to disease risk and progression.”

    Conducting the study

    The researchers gathered data on demographics, lifestyle and physical activity from 555 people with PD in the Parkinson’s Environment and Gene (PEG) Studies.

    This long-term research project was a joint effort of the UCLA Fielding School of Public Health and the UCLA Neurology Department. Its goal was to learn more about what causes the factors that contribute to PD.

    Using this data, Dr. Hu and colleagues calculated DNA-based measures that acted as stand-ins for immune system signals known as cytokines.

    Next, they compared data from physically active study participants to data from less active participants.

    This made it possible to see whether physical activity is linked to immune-related DNA markers – which is exactly what they found, according to Dr. Hu.

    The findings suggest that physical activity lowers chronic inflammation, which may slow disease progression.

    What this means for patients 

    People with PD should consider doing higher-intensity activities, such as fast walking, seated dancing or chair aerobics, if possible.

    “We found that having a higher day-to-day activity level is associated with both lower levels of pro-inflammatory signals and higher levels of anti-inflammatory signals,” Dr. Hu says.

    Some of these signals have been linked to the progression of PD, he says. This points to regular physical activity being helpful in managing the condition.

    Overall, says Dr. Hu, patients should know that “staying physically active could be a simple yet powerful way to improve long-term health outcomes in PD.”

    Another of the study’s coauthors – Jeff Bronstein, MD, PhD – agrees about the importance of exercise for people with PD.

    Dr. Bronstein is the director of movement disorders at UCLA’s David Geffen School of Medicine.

    “We have yet to find a medication that can slow the progression of the disease,” he says. “However, we have several therapies that can improve symptoms and help maintain a high quality of life,”

    Physical activity is the one treatment that slows disease progression, but we simply do not understand how it works, he notes.

    “This study found that physical activity is associated with changes in our DNA that alters inflammation,” he continues.

    “Inflammation may contribute to the cause of PD – and therefore, these changes in DNA might give us insight into how physical activity slows disease progression. It might also be important in other diseases as well.”

    Working together to help people with PD

    A study like this would not be possible without high-quality data, notes Dr. Hu.

    All the data was collected from the PEG study, which enrolled residents from Fresno, Tulare and Kern counties in Central California.

    The PEG study brought researchers and community members together to learn more about PD. Trained professionals gathered a wide range of information, according to Dr. Hu.

    Detailed neurological examinations for PD patients were performed by UCLA movement disorder specialists at the UCLA Department of Neurology at the initial visit and at follow-up visits.

    Their expertise was crucial in confirming that participants had PD symptoms.

    “Their in-depth knowledge of PD diagnosis, treatment and pathology was instrumental in interpreting some of the study’s results,” Dr. Hu says.

    “Drs. Ritz and Bronstein have contributed a strong clinical perspective to the conversation, connecting the observed changes in cytokine levels to potential and meaningful differences in the progression of PD.”

    Discussions with experts were key to understanding the study results, he adds, especially around the changes to immune cells like B-cells and T-cells.

    “These are vital pathological alterations observed in PD patients.”

    Continue Reading

  • Women Face 45% Higher Mortality Risk From Beta-Blockers After Heart Attack

    Women Face 45% Higher Mortality Risk From Beta-Blockers After Heart Attack

    Women treated with beta-blockers (β-blockers) for post-myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF) have a 45% increased risk of MI, heart failure hospitalization, or death compared with men, according to new study findings. The results, published in the European Heart Journal, suggest a need to re-evaluate β-blocker use in post-MI women without reduced LVEF, with a view toward more sex-specific prescribing strategies.1

    Bottle of metroprolol | Image Credit: © Sherry Young – stock.adobe.com

    “Despite the underlying reasons not being fully understood, it is well established that women and men do not receive equal management—including pharmacological therapies—following an ACS [acute coronary syndrome],” the authors discussed. “Moreover, although findings vary across studies, several reports suggest that women may experience worse long-term outcomes than men after ACS.”1

    Cardiovascular disease (CVD) affects nearly 60 million women in the United States alone, and only 44% see it as a significant health threat for women. This is largely in response to the prioritization of male enrollment in CVD clinical trials due to dissimilarities in women’s and men’s hormones, platelet reactivity, P2Y12 inhibitors, and the likelihood of developing comorbidities, which greatly impact responses to treatment. Continued evidence shows that women with cardiovascular conditions have increased adverse responses to cardiovascular drugs compared with men, with a risk that is 1.5 to 1.7 times higher. This underscores the critical need for inclusion of women in cardiovascular trials, as well as sex-based treatment guidelines.2

    The authors assessed a pre-specified sex-specific subgroup analysis of REBOOT (NCT03596385), the largest randomized trial evaluating the effect of beta-blockers after acute MI with LVEF less than 40%. The assessment included a total of 8438 patients, of whom 1627 were older, had more comorbidities, and received fewer guideline-based therapies than men.1,3

    Over nearly 4 years of follow-up, women who had a heart attack were more likely than men to experience serious health problems such as death, another heart attack, or hospitalization for heart failure. Among women, these events happened more often in those who were taking beta-blockers compared with those who were not (about 30 vs 21 cases per 1,000 patients each year). This means women on beta-blockers had about a 45% higher risk of adverse events.1

    For men, there was no meaningful difference between taking beta-blockers or not. The higher risk seen in women was mostly due to increased deaths, and it was especially noticeable in women who had normal heart pumping function and in those who received higher doses of beta-blockers.1

    “Despite women and men differing with respect to baseline risk, causes, and prognosis of MI, current guidelines do not differentiate between the use of beta-blockers in women and men,” wrote the authors. “… our study provides robust evidence of an interaction between sex and beta-blocker therapy and suggests an increased risk of the composite endpoint of all-cause death, MI, or HF hospitalization, mainly in women with preserved LVEF receiving higher doses of beta-blockers.”1

    REFERENCES
    1. Rossello X, Dominguez-Rodriguez A, Latini R, et al. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. European Heart Journal. August 30, 2025. Doi:10.1093/eurheartj/ehaf673
    2. Gerlach A. Closing the gap: Addressing underrepresentation of women in cardiovascular clinical trials. Pharmacy Times. May 24, 2024. Accessed September 3, 2025. https://www.pharmacytimes.com/view/closing-the-gap-addressing-underrepresentation-of-women-in-cardiovascular-clinical-trials
    3. TREatment With beta-blockers After myOcardial Infarction withOut Reduced Ejection fraction. Updated June 6, 2025. Accessed September 3, 2025. https://clinicaltrials.gov/study/NCT03596385

    Continue Reading

  • I tried Jsaux’s new anti-glare Switch 2 screen protector, and it revealed a glaring bug

    I tried Jsaux’s new anti-glare Switch 2 screen protector, and it revealed a glaring bug

    I have a dead cockroach in my ceiling, and I only noticed it thanks to a Switch 2 screen protector that, ironically, is supposed to tame reflections. The protector in question is a pre-production sample of the Jsaux Obsidian AR screen protector, which is coming in October for $21.99.

    The company claims it’s better than standard screen protectors because it features a similar physical vapor deposition (PVD) coating found in the Apple Studio Display. It’s supposed to reduce glare while retaining a glossy appearance — an ideal combination for gamers, since you can’t always choose where you’ll play games.

    In reality, this pre-production screen protector boasts minor improvements that are easy to miss. Obsidian AR slightly reduces the intensity of reflections hitting the screen that could otherwise distract me during gameplay. However, I noticed these differences in photos more than I did while actively using the Switch 2.

    One thing I did have the misfortune to notice as I played my Switch 2 with the screen protector equipped was the roach in my ceiling. That little sucker has probably been dead for a while and I only just noticed. In defense of Jsaux’s claims, it makes the bold LED tube illuminating the trapped roach a little dimmer and tougher to pick out, but not nearly enough to wipe this encounter from my memory.

    I won’t go as far as to say that the Obsidian AR isn’t worth your money, having only tried an early version. Everyone’s tolerance for glare is different, but I’m skeptical that the differences are worth paying for compared to cheaper alternatives. To reiterate, just one of these protectors will cost $21.99 while you can get a three-pack of good-enough tempered glass protectors for under $10.

    Photography by Cameron Faulkner / The Verge

    Continue Reading

  • Laufey conjures smoky jazz lounges of yesteryear, Bar Italia brings the twang, LA’s Massage are here for those w/ *feelings* about “C86.”

    Laufey conjures smoky jazz lounges of yesteryear, Bar Italia brings the twang, LA’s Massage are here for those w/ *feelings* about “C86.”

    Laufey – “Seems Like Old Times” 

    This track from Icelandic-Chinese, Grammy-winning artist Laufey is onomatopoetic. By which we mean, self-referential, or perhaps, meta. Titled “Seems Like Old Times,” the lyrics describe the nostalgia one may experience when reunited with a past lover… And the song itself does indeed, sound and feel like “old times,” as it is expertly crafted in the style of smokey jazz lounges of yesteryear.  Catch Laufey’s tour in LA later this month, with support from Suki Waterhouse. (P.S. It’s pronounced lay-vay. You’re welcome.)


    Bar Italia – “Fundraiser”

    This twangy track from collaborative singer-songwriter trio Bar Italia features ultra-indie guitars, room-filling cymbal smashes, and alternating male-female vocals to keep you stimming in a protosexual, tingly kinda way. Nina Cristante, Jezmi Tarik Fehmi, and Sam Fenton made this excellent single the opener on their album, and named the album (out now) after a classic film about another fabulous trio: Some Like It Hot. LA folks can catch them at the Bellwether in November. 


    Hannah Judge, the artist behind Fanclubwallet, belies the seriously challenging reality (a bout of chronic illness) that inspired this excellent late summer single with a hopeful, hooky, and dare-we-say bouncy musical style. This ultra-catchy track is infused with the kind of ‘90s charm that’ll have you reaching for your velvet choker and your most well-worn pair of Docs. 


    Lionmilk – “all i have”

    We love when a song feels lifted right out of a jam space, a golden-hour lit room that might be layered with rugs and dotted with lightly sweating cocktails on cork coasters… And that’s this open-hearted groover from Lionmik. The song may feel casual and unpretentious, but Lionmilk is accomplished as a musician — the artist produced, wrote, and performed every instrument on When The Flowers Bloom, his first album at his new musical home of Stones Throw Records. Give it a listen and tap into what you’ve got to give. 


    Massage – “Daffy Duck”

    Massage! The LA indie-poppers are back with new music, and this big-sound single is leading the charge. It’s no wonder that the band cite The Cure and Echo and the Bunnymen among their influences, but it’s also sweet to read that they, “have always seen themselves as music fans rather than proper “musicians.” In our opinion, the band may be taking the humility a step too far there, as this track is stellar in musicality, production, execution, and that ineffable quality… ear. Click play for a blue-hued chune that’ll have you dancing Molly Ringwald style… You know the one.


    Continue Reading

  • Snowflake Appoints Brian Robins as Chief Financial Officer

    Snowflake Appoints Brian Robins as Chief Financial Officer

    No-Headquarters/BOZEMAN, Mont. – September 3, 2025 – Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced that Brian Robins is joining the company as Chief Financial Officer, effective September 22. In this role, Mr. Robins will be responsible for shaping Snowflake’s financial strategies to support its growth and long-term health, and will lead the global finance organization, including planning, treasury, tax, reporting, and investor relations. Snowflake also announced that Mike Scarpelli is retiring as Chief Financial Officer, effective September 22. Mr. Scarpelli will stay a Snowflake employee for a period of time to support continuity and a smooth transition, then will take on an advisory role at Snowflake.

    “We’re incredibly confident in our next chapter of growth with Brian taking the helm as our new Chief Financial Officer,” said Sridhar Ramaswamy, CEO of Snowflake. “Brian’s deep commitment to operational rigor and long-term high growth aligns perfectly with the strategic direction of Snowflake. We have an enormous opportunity ahead of us and he’ll be an invaluable partner in our mission to empower every enterprise with data and AI. I would also like to thank Mike for his years of service and deep impact on Snowflake.”

    “Snowflake is at the center of the AI revolution, and I couldn’t be more excited to join the team,” Mr. Robins said. “The work Snowflake is doing to empower organizations around the world with data and AI is transformational. I am thrilled to be a part of this hyper-growth phase and am committed to helping the company scale efficiently to achieve its vision.”

    Mr. Robins has served as Chief Financial Officer of GitLab Inc. (GitLab), a technology company, since October 2020, he is responsible for GitLab’s financial, data and business systems functions, including accounting, tax, treasury, corporate finance and investor relations.  Prior to GitLab, Mr. Robins was CFO of Sisense, Cylance, AlienVault, and Verisign (VRSN), a Nasdaq listed company.  He currently serves on the GitLab Foundation Board of Directors and the Board of Directors of ID.me as a member and as audit committee chair. Mr. Robins is a special advisor at Brighton Park Capital, L.P. and on the Advisory Council at ForgePoint Capital Cybersecurity. 

    Mr. Robins holds a B.S. degree in Finance from Lipscomb University and an M.B.A from Vanderbilt University.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results or outcomes to be materially different from any future results or outcomes expressed or implied by the forward-looking statements. Further information on such risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those included in or contemplated by the forward-looking statements contained in this press release are included in the filings and reports we make with the Securities and Exchange Commission from time to time. Forward-looking statements speak only as of the date the statements are made and are based on information available to us at the time those statements are made and/or our management’s good faith belief as of that time with respect to future events. Except as required by law, we undertake no obligation, and do not intend, to update these forward-looking statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Continue Reading

  • Salesforce posts an earnings beat – but stock drop shows investors are still wary of AI adoption

    Salesforce posts an earnings beat – but stock drop shows investors are still wary of AI adoption

    By Christine Ji

    Salesforce comes up a bit shy with its sales outlook for the current quarter

    Salesforce surpassed analysts’ expectations for revenue and earnings on Wednesday.

    Salesforce Inc.’s earnings beat on Wednesday proved that it’s making progress on its transition from a traditional software company to an agentic artificial-intelligence platform, but the results weren’t enough to satisfy investors as the company’s guidance came up a hair short.

    Salesforce (CRM) reported second-quarter revenue of $10.24 billion, a 10% increase year over year. Analysts tracked by FactSet were anticipating $10.14 billion for the quarter.

    The company’s current remaining performance obligations (cRPO), or the amount of expected revenue in the next year from services not yet delivered, was $29.4 billion, up 11% year over year and beating the consensus of $29.2 billion.

    However, the forward-looking estimate for next quarter came in slightly softer than analysts expected. Salesforce projects $10.24 billion to $10.29 billion in revenue for the fiscal third quarter, which at the midpoint is below Wall Street’s expectations of $10.29 billion.

    For the full year, the company raised the low end of its revenue guidance to between $41.1 billion and $41.3 billion in total revenue, indicating a 8.5% to 9% increase. Last quarter, the low end of Salesforce’s full-year outlook was $41.0 billion.

    Shares of Salesforce dropped as much as 5% in after-hours trading.

    Investor sentiment in the software industry has been low overall as AI technology appears poised to disrupt establish software business models. While many Wall Street analysts have been bullish on the stock, Salesforce shares have declined 22% year to date.

    Matt Stucky, chief portfolio manager of equities at Northwestern Mutual, told MarketWatch on Wednesday before the earnings announcement that it would take a noticeable amount of “top-line revenue acceleration” for Salesforce to “refute the bear argument” about the competitive threat of AI.

    Salesforce’s revenue growth did accelerate in the latest quarter, to 10% on a reported basis and 9% on a constant-currency basis, versus 8% growth for both in the fiscal first quarter. But investors perhaps wanted more.

    Jefferies analyst Brent Thill expressed a similar view in a note from last week, writing that investors would be watching for cRPO growth greater than 10% and proof of AI monetization.

    -Christine Ji

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    09-03-25 1634ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading